symbol,statement_type,period_end,line_item,value
NATCOPHARM.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.178057
NATCOPHARM.NS,income,2025-03-31 00:00:00,Normalized EBITDA,25505000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Total Unusual Items,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,18854000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,2352000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,6898000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,EBITDA,25505000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,EBIT,23153000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Net Interest Income,-239000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Interest Expense,239000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Interest Income,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Normalized Income,18854000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,18854000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Total Expenses,24687000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Rent Expense Supplemental,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Diluted Average Shares,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Basic Average Shares,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Diluted EPS,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Basic EPS,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,18854000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,18854000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Net Income,18854000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Minority Interests,20000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,18834000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,18834000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Tax Provision,4080000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Pretax Income,22914000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,3545000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Special Income Charges,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Other Special Charges,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Write Off,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,-239000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Total Other Finance Cost,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,239000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Operating Income,19608000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Operating Expense,17789000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Other Operating Expenses,9492000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,2352000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,2352000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Research And Development,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Selling General And Administration,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,
NATCOPHARM.NS,income,2025-03-31 00:00:00,General And Administrative Expense,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Rent And Landing Fees,
NATCOPHARM.NS,income,2025-03-31 00:00:00,Gross Profit,37397000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Cost Of Revenue,6898000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Total Revenue,44295000000.0
NATCOPHARM.NS,income,2025-03-31 00:00:00,Operating Revenue,44295000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.170421
NATCOPHARM.NS,income,2024-03-31 00:00:00,Normalized EBITDA,18795000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Total Unusual Items,-75000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-75000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,13883000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,1868000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,7166000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,EBITDA,18795000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,EBIT,16927000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Net Interest Income,-192000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Interest Expense,192000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Interest Income,1010000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Normalized Income,13883000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,13883000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Total Expenses,24342000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Rent Expense Supplemental,59000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Diluted Average Shares,179506077.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Basic Average Shares,179506077.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Diluted EPS,77.34
NATCOPHARM.NS,income,2024-03-31 00:00:00,Basic EPS,77.34
NATCOPHARM.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,13883000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,13883000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Net Income,13883000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Minority Interests,0.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,13883000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,13883000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Tax Provision,2852000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Pretax Income,16735000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,1281000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Special Income Charges,-68000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Other Special Charges,17000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Write Off,51000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-192000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Total Other Finance Cost,72000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,192000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,1010000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Operating Income,15646000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Operating Expense,17176000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Other Operating Expenses,10058000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,1868000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,1868000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Research And Development,1417000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Selling General And Administration,2683000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,1530000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,General And Administrative Expense,1153000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Rent And Landing Fees,59000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Gross Profit,32822000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Cost Of Revenue,7166000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Total Revenue,39988000000.0
NATCOPHARM.NS,income,2024-03-31 00:00:00,Operating Revenue,39988000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Tax Effect Of Unusual Items,-850446.687551
NATCOPHARM.NS,income,2023-03-31 00:00:00,Tax Rate For Calcs,0.170089
NATCOPHARM.NS,income,2023-03-31 00:00:00,Normalized EBITDA,10357000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Total Unusual Items,-5000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-5000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,7153000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Reconciled Depreciation,1638000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Reconciled Cost Of Revenue,7455000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,EBITDA,10352000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,EBIT,8714000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Net Interest Income,367000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Interest Expense,95000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Interest Income,512000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Normalized Income,7157149553.312449
NATCOPHARM.NS,income,2023-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,7153000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Total Expenses,19068000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Rent Expense Supplemental,49000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Diluted Average Shares,182552365.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Basic Average Shares,182552365.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Diluted EPS,39.18
NATCOPHARM.NS,income,2023-03-31 00:00:00,Basic EPS,39.18
NATCOPHARM.NS,income,2023-03-31 00:00:00,Diluted NI Availto Com Stockholders,7153000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Net Income Common Stockholders,7153000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Net Income,7153000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Minority Interests,0.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Net Income Including Noncontrolling Interests,7153000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Net Income Continuous Operations,7153000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Tax Provision,1466000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Pretax Income,8619000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Other Non Operating Income Expenses,141000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Special Income Charges,47000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Other Special Charges,-178000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Write Off,131000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Net Non Operating Interest Income Expense,367000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Total Other Finance Cost,50000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Interest Expense Non Operating,95000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Interest Income Non Operating,512000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Operating Income,7901000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Operating Expense,11613000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Other Operating Expenses,2226000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Depreciation And Amortization In Income Statement,1638000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Depreciation Income Statement,1638000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Research And Development,902000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Selling General And Administration,2030000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Selling And Marketing Expense,961000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,General And Administrative Expense,1069000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Rent And Landing Fees,49000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Gross Profit,19514000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Cost Of Revenue,7455000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Total Revenue,26969000000.0
NATCOPHARM.NS,income,2023-03-31 00:00:00,Operating Revenue,26969000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Tax Effect Of Unusual Items,38219584.569733
NATCOPHARM.NS,income,2022-03-31 00:00:00,Tax Rate For Calcs,0.159248
NATCOPHARM.NS,income,2022-03-31 00:00:00,Normalized EBITDA,3340000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Total Unusual Items,240000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Total Unusual Items Excluding Goodwill,240000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,1700000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Reconciled Depreciation,1426000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Reconciled Cost Of Revenue,6815000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,EBITDA,3580000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,EBIT,2154000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Net Interest Income,213000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Interest Expense,132000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Interest Income,390000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Normalized Income,1498219584.569733
NATCOPHARM.NS,income,2022-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,1700000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Total Expenses,17641000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Rent Expense Supplemental,32000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Diluted Average Shares,182409089.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Basic Average Shares,182372169.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Diluted EPS,9.32
NATCOPHARM.NS,income,2022-03-31 00:00:00,Basic EPS,9.32
NATCOPHARM.NS,income,2022-03-31 00:00:00,Diluted NI Availto Com Stockholders,1700000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Net Income Common Stockholders,1700000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Net Income,1700000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Minority Interests,0.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Net Income Including Noncontrolling Interests,1700000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Net Income Continuous Operations,1700000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Tax Provision,322000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Pretax Income,2022000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Other Non Operating Income Expenses,56000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Special Income Charges,228000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Other Special Charges,-427000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Write Off,199000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Net Non Operating Interest Income Expense,213000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Total Other Finance Cost,45000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Interest Expense Non Operating,132000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Interest Income Non Operating,390000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Operating Income,1408000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Operating Expense,10826000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Other Operating Expenses,2292000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Depreciation And Amortization In Income Statement,1426000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Depreciation Income Statement,1426000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Research And Development,1769000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Selling General And Administration,1255000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Selling And Marketing Expense,437000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,General And Administrative Expense,818000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Rent And Landing Fees,32000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Gross Profit,12234000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Cost Of Revenue,6815000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Total Revenue,19049000000.0
NATCOPHARM.NS,income,2022-03-31 00:00:00,Operating Revenue,19049000000.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Tax Effect Of Unusual Items,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Tax Rate For Calcs,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Normalized EBITDA,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Total Unusual Items,203000000.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Total Unusual Items Excluding Goodwill,203000000.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Reconciled Depreciation,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Reconciled Cost Of Revenue,
NATCOPHARM.NS,income,2021-03-31 00:00:00,EBITDA,
NATCOPHARM.NS,income,2021-03-31 00:00:00,EBIT,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Net Interest Income,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Interest Expense,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Interest Income,566000000.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Normalized Income,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Total Expenses,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Rent Expense Supplemental,30000000.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Diluted Average Shares,182494899.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Basic Average Shares,182158796.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Diluted EPS,24.16
NATCOPHARM.NS,income,2021-03-31 00:00:00,Basic EPS,24.2
NATCOPHARM.NS,income,2021-03-31 00:00:00,Diluted NI Availto Com Stockholders,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Net Income Common Stockholders,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Otherunder Preferred Stock Dividend,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Net Income,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Minority Interests,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Net Income Including Noncontrolling Interests,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Net Income Continuous Operations,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Tax Provision,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Pretax Income,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Other Non Operating Income Expenses,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Special Income Charges,203000000.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Other Special Charges,-320000000.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Write Off,117000000.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Net Non Operating Interest Income Expense,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Total Other Finance Cost,45000000.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Interest Expense Non Operating,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Interest Income Non Operating,566000000.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Operating Income,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Operating Expense,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Other Operating Expenses,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Depreciation And Amortization In Income Statement,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Depreciation Income Statement,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Research And Development,1473000000.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Selling General And Administration,906000000.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Selling And Marketing Expense,341000000.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,General And Administrative Expense,565000000.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Rent And Landing Fees,30000000.0
NATCOPHARM.NS,income,2021-03-31 00:00:00,Gross Profit,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Cost Of Revenue,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Total Revenue,
NATCOPHARM.NS,income,2021-03-31 00:00:00,Operating Revenue,
